Rafael Holdings, Inc. 8-K

What Happened Rafael Holdings, Inc. (RFL) filed an 8‑K on April 22, 2026 reporting results of operations and financial condition and furnishing a press release under Regulation FD. The press release announces that the Company’s subsidiary, Cyclo Therapeutics, LLC, entered into an exclusive licensing agreement with the Massachusetts Institute of Technology (MIT) covering U.S. Patent No.12285440, which relates to the use of cyclodextrins in patients with Alzheimer’s disease who carry an ApoE4 genetic mutation. The release is furnished as Exhibit 99.1 to the 8‑K.

Key Details

• Filing date: April 22, 2026 (Form 8‑K, Accession 0001213900-26-046380).
• Subsidiary: Cyclo Therapeutics, LLC entered an exclusive license with MIT.
• Patent: U.S. Patent No.12285440 — covers use of cyclodextrins in ApoE4 Alzheimer’s patients.
• Disclosure type: Information furnished under Item 7.01 (Regulation FD); Item 2.02 notes results of operations and financial condition and includes forward‑looking statement cautions.

Why It Matters This 8‑K formally notifies investors that Rafael’s subsidiary secured exclusive rights to an MIT patent targeting a genetically defined subgroup of Alzheimer’s patients (ApoE4 carriers). That IP could be material to Cyclo Therapeutics’ development strategy and future commercialization prospects if the underlying therapy advances, although the filing furnishes (does not “file”) the press release and includes standard forward‑looking statement cautions. Investors should monitor subsequent filings or disclosures for financial details, development updates, regulatory steps, or licensing terms.